<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Overview of established risk factors for cardiovascular disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Overview of established risk factors for cardiovascular disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Overview of established risk factors for cardiovascular disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter WF Wilson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joann G Elmore, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Christopher P Cannon, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sara Swenson, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Susan B Yeon, MD, JD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 11, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cardiovascular disease (CVD) is common in the general population worldwide, affecting the majority of adults past the age of 60 years. In 2012 and 2013, CVD was estimated to result in 17.3 million deaths worldwide on an annual basis [
         <a href="#rid1">
          1-3
         </a>
         ]. The 2019 Heart Disease and Stroke Statistics update of the American Heart Association (AHA) reported that 48 percent of persons ≥20 years of age in the United States have CVD (which includes coronary heart disease [CHD] [
         <a href="#rid4">
          4
         </a>
         ], heart failure, stroke, and hypertension) [
         <a href="#rid4">
          4
         </a>
         ]. The reported prevalence increases with age for both males and females.
        </p>
        <p>
         As a diagnostic category, CVD includes four major areas:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CHD, manifested by myocardial infarction (MI), angina pectoris, and coronary death
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cerebrovascular disease, manifested by stroke and transient ischemic attack
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peripheral artery disease, manifested by intermittent claudication
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aortic atherosclerosis and thoracic or abdominal aortic aneurysm
        </p>
        <p>
        </p>
        <p>
         An overview of the established risk factors for CVD is presented here. An overview of the possible emerging CVD risk factors, data supporting the importance of the individual risk factors (eg, hyperlipidemia, hypertension, smoking), coronary risk factors of particular importance in women and in young patients, and estimation of coronary risk in an individual patient are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/16307.html" rel="external">
          "Overview of possible risk factors for cardiovascular disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">
          "Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3852.html" rel="external">
          "Overview of hypertension in adults", section on 'Treatment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1468.html" rel="external">
          "Overview of atherosclerotic cardiovascular risk factors in females"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/50.html" rel="external">
          "Coronary artery disease and myocardial infarction in young people"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1546.html" rel="external">
          "Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/114029.html" rel="external">
          "Cardiovascular disease risk assessment for primary prevention: Risk calculators"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H732603091">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lifetime risk of overall cardiovascular disease (CVD) approaches 50 percent for persons age 30 years without known CVD [
         <a href="#rid5">
          5
         </a>
         ]. Coronary heart disease (CHD) accounts for approximately one-third to one-half of the total cases of CVD, with ischemic heart disease as the number-one cause of death in adults from both low-, middle-, and high-income countries [
         <a href="#rid4">
          4,6
         </a>
         ]. The lifetime risk of CHD was illustrated in a study of 7733 participants, age 40 to 94, in the Framingham Heart Study who were initially free of CHD [
         <a href="#rid7">
          7
         </a>
         ]. The lifetime risk for individuals at age 40 was 49 percent in men and 32 percent in women. Even those who were free from CHD at age 70 had a non-trivial lifetime risk of developing CHD (35 and 24 percent in males and females, respectively). Similar findings have been reported in a meta-analysis of 18 cohorts involving over 250,000 adults [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1546.html" rel="external">
          "Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach", section on 'Lifetime risk'
         </a>
         .)
        </p>
        <p>
         Autopsy data have documented the early onset of atherosclerosis, beginning in the second and third decades of life, although the prevalence of anatomic CHD has decreased over time. In an analysis of 3832 autopsies performed on United States military personnel (98 percent male, mean age 26 years) who died of combat or unintentional injuries between October 2001 and August 2011, the prevalence of any coronary atherosclerosis was 8.5 percent [
         <a href="#rid9">
          9
         </a>
         ]. This represents a marked decline in the prevalence of autopsy-documented CHD compared with the rates seen during the Korean War in the 1950s (77 percent) and the Vietnam War in the 1960s (45 percent) [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         Despite increases in longevity and decreases in age-specific death rates from CVD, CHD, and stroke since 1975, CVD and its related complications remain highly prevalent and expensive to treat [
         <a href="#rid4">
          4,10-14
         </a>
         ]. In one cohort of over 1.9 million persons age 30 years or older free of known baseline CVD who were followed for a median of six years, the majority of initial CVD presentations were neither myocardial infarction (MI) nor stroke [
         <a href="#rid15">
          15
         </a>
         ]. These presentations, which included angina  (
         <a class="graphic graphic_table graphicRef115007" href="/z/d/graphic/115007.html" rel="external">
          table 1
         </a>
         ), heart failure, peripheral arterial disease, transient ischemic attack, and abdominal aortic aneurysm, along with some less common manifestations, represented 66 percent of the initial CVD presentations.
        </p>
        <p>
         While CVD remains the leading cause of death in most developed countries, mortality from acute MI appears to have decreased by as much as 50 percent in the 1990s and 2000s. Among 49 countries in Europe and northern Asia, over four million persons die annually from CHD [
         <a href="#rid16">
          16
         </a>
         ]. In the United States, approximately 1.5 million persons suffer a heart attack or stroke annually, resulting in over 250,000 deaths [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p>
         Along with the improvements in mortality associated with the initial CVD event, the prevalence of CVD is rapidly increasing in resource-limited countries as well [
         <a href="#rid19">
          19-21
         </a>
         ]. Between 1990 and 2010, it is estimated that the global burden of CHD increased by 29 percent due to increases in therapy and longevity along with global population growth [
         <a href="#rid22">
          22
         </a>
         ]. Additionally, 2010 data showed significant regional variation in CHD mortality, with the largest number of CHD deaths seen in South Asia but the highest rates of CHD mortality seen in Eastern Europe and Central Asia [
         <a href="#rid23">
          23
         </a>
         ]. In a study of 156,424 persons from 17 countries (3 high-income, 10 middle-income, 4 low-income), the INTERHEART risk score (for assessing risk factors) was highest in high-income countries and lowest in low-income countries [
         <a href="#rid24">
          24
         </a>
         ]. However, CVD events and mortality appeared inversely related to the INTERHEART score, with significantly lower rates of CVD events and mortality in high-income countries compared with middle- and low-income countries, a finding which is purportedly due to greater risk factor modification in high-income countries.
        </p>
        <p class="headingAnchor" id="H4874544">
         <span class="h1">
          NONCORONARY ATHEROSCLEROTIC DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients without known coronary heart disease (CHD) have a risk of subsequent cardiovascular events that is comparable to that of patients with established CHD [
         <a href="#rid25">
          25
         </a>
         ]. Noncoronary atherosclerotic arterial disease, a diffuse condition that involves the entire arterial circulation, includes patients with carotid artery disease, peripheral artery disease, or abdominal aortic aneurysm. The presence of clinical atherosclerosis in one vascular territory generally indicates an increased likelihood that it exists elsewhere, since the risk factors are generally the same.
        </p>
        <p>
         Concurrent risk factors should be treated aggressively in such patients. (See
         <a class="medical medical_review" href="/z/d/html/15188.html" rel="external">
          "Management of asymptomatic abdominal aortic aneurysm", section on 'Introduction'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1113.html" rel="external">
          "Management of asymptomatic extracranial carotid atherosclerotic disease", section on 'Intensive medical therapy and follow-up'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8210.html" rel="external">
          "Management of claudication due to peripheral artery disease", section on 'Risk for progression and risk modification'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H579647">
         <span class="h1">
          PREVALENCE AND IMPACT OF CARDIOVASCULAR RISK FACTORS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevalence of modifiable risk factors
         </strong>
         –
         <strong>
         </strong>
         Modifiable risk factors are common in the general population [
         <a href="#rid26">
          26-28
         </a>
         ]. In two population-based cohort studies of White non-Hispanic United States adults (Framingham Heart Study and Third National Health and Nutrition Examination Survey [NHANES III]), approximately 60 percent of men and 50 percent of women without coronary artery disease (CAD) had one to two of five major coronary heart disease (CHD) risk factors (blood pressure, low-density lipoprotein [LDL] and high-density lipoprotein [HDL] cholesterol, glucose intolerance, and smoking)  (
         <a class="graphic graphic_table graphicRef91637" href="/z/d/graphic/91637.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid27">
          27
         </a>
         ]. In addition, 26 percent of men and 41 percent of women had at least one "borderline" risk factor (defined as systolic pressure 120 to 139 mmHg, diastolic pressure 80 to 89 mmHg, LDL cholesterol 100 to 159 mg/dL [2.6 to 4.1 mmol/L], HDL cholesterol 40 to 59 mg/dL [1.0 to 1.5 mmol/L], impaired fasting glucose without overt diabetes, and a past history of smoking)  (
         <a class="graphic graphic_table graphicRef91638" href="/z/d/graphic/91638.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Impact of modifiable risk factors
         </strong>
         – Modifiable risk factors account for over 50 percent of cardiovascular events and up to 90 percent of CHD events.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Modifiable risk factors account for more than half of cardiovascular disease events and cardiovascular mortality [
         <a href="#rid29">
          29-31
         </a>
         ]. As an example, in an analysis of a global cohort of over 1,500,000 individuals, five modifiable risk factors (hypercholesterolemia, diabetes, hypertension, obesity, and smoking) accounted for 57 and 53 percent of 10-year incident cardiovascular disease [
         <a href="#rid29">
          29
         </a>
         ]. Similarly, in a second global cohort of individuals from 21 countries, approximately 70 percent of cardiovascular disease cases were attributable to modifiable risk factors [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Modifiable risk factors may account for up to 90 percent of CHD events. An analysis of the Framingham Heart Study and the NHANES III cohort estimated that over 90 percent of CHD events occurred in individuals with at least one modifiable risk factor [
         <a href="#rid27">
          27
         </a>
         ]. Conversely, few events occurred in those with no risk factors, although the complete absence of any elevated or borderline risk factor was rare (0 to 0.4 percent). Similarly, in the INTERHEART study of individuals from 52 countries, nine potentially modifiable factors accounted for over 90 percent of the population-attributable risk of a first MI. Smoking, dyslipidemia, hypertension, diabetes, abdominal obesity, and psychosocial factors were associated with the greatest risk [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Increased risk with multiple risk factors
         </strong>
         – Multiple risk factors confer increased cardiovascular risk and, conversely, the absence of major risk factors predicts a much lower risk of CHD [
         <a href="#rid27">
          27,28,32-34
         </a>
         ]. As an example, in a cohort study of 20,000 adults, the presence of two or three risk factors (cholesterol ≥200 mg/dL [≥5.2 mmol/L], elevated blood pressure [≥120/80 mmHg], and cigarette smoking) was associated with a marked increase in the relative risk of CHD (5.5 and 5.7), cardiovascular disease (CVD; 4.1 and 4.5), and all-cause mortality (3.2 and 2.3) in men and women, respectively [
         <a href="#rid33">
          33
         </a>
         ]. A cohort study of 380,000 individuals from Asia, Australia, and New Zealand reported similar results [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          ESTABLISHED RISK FACTORS FOR ATHEROSCLEROTIC CVD
         </span>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          General principles
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atherosclerosis is responsible for almost all cases of coronary heart disease (CHD). This insidious process begins with fatty streaks that are first seen in adolescence; these lesions progress into plaques in early adulthood, and culminate in thrombotic occlusions and coronary events in middle age and later life. (See
         <a class="medical medical_review" href="/z/d/html/13603.html" rel="external">
          "Pathogenesis of atherosclerosis"
         </a>
         .)
        </p>
        <p>
         A variety of factors, often acting in concert, are associated with an increased risk for atherosclerotic plaques in coronary arteries and other arterial beds  (
         <a class="graphic graphic_figure graphicRef55353" href="/z/d/graphic/55353.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid35">
          35
         </a>
         ]. Risk factor assessment is useful in adults to guide therapy for dyslipidemia, hypertension, and diabetes, and multivariate formulations can be used to help estimate risk for coronary disease events [
         <a href="#rid36">
          36,37
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1546.html" rel="external">
          "Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach"
         </a>
         .)
        </p>
        <p>
         As an example, a 12-year follow-up of 14,786 Finnish males and females, age 25 to 64, found that the incidence of CHD was threefold higher in men than women and mortality was fivefold higher [
         <a href="#rid38">
          38
         </a>
         ]. The relative difference in CHD risk between the sexes was largest among the youngest subjects (25 to 49 years), but the absolute difference was largest in the older age group due to a higher prevalence (60 to 64 years). Almost half of the difference in CHD risk between males and females was associated with the sex differences in cardiovascular risk factors, particularly the high-density lipoprotein (HDL)/total cholesterol ratio and smoking. Differences in serum total cholesterol, blood pressure, body mass index, and prevalence of diabetes accounted for approximately one-third of the age-related increase in CHD prevalence in men and 50 to 60 percent in women.
        </p>
        <p>
         Based upon the absolute, relative, and attributable risks imposed by the various risk factors, concepts of "normal" have evolved from usual or average to more optimal values associated with long-term freedom from disease. As a result, optimal blood pressure, blood glucose, and lipid values have been revised downward in the past 20 years [
         <a href="#rid39">
          39-41
         </a>
         ].
        </p>
        <p>
         Some authors have asserted that approximately one-half of all patients suffering a manifestation of CHD have no established risk factors other than age and sex, a claim that has contributed to efforts to identify other markers of cardiovascular risk [
         <a href="#rid42">
          42,43
         </a>
         ]. However, the accuracy of this assertion has been challenged by the results of several analyses suggesting the prevalence of major risk factors in patients with CHD to be higher than 75 percent [
         <a href="#rid44">
          44-46
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an observational study from the National Registry of Myocardial Infarction that enrolled more than 540,000 patients between 1994 and 2006 who presented with a first myocardial infarction (MI) with no prior cardiovascular disease, 86 percent had one of five major risk factors (hypertension, smoking, dyslipidemia, diabetes mellitus, or family history of CHD) [
         <a href="#rid46">
          46
         </a>
         ]. Among the nearly 51,000 patients who died prior to hospital discharge, there was a significant inverse relationship between the risk of death and the number of major risk factors present, with patients having 0 to 2 risk factors significantly more like to die compared with persons with all five risk factors (adjusted odds ratio [OR] of death for zero risk factors 1.54, 95% CI 1.23-1.94).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A report based upon data from three observational studies (the Framingham Heart Study, the Multiple Risk Factor Intervention Trial [MRFIT], and the Chicago Heart Association Detection Project in Industry) included more than 380,000 subjects, 21,000 of whom died of CHD [
         <a href="#rid44">
          44
         </a>
         ]. Major CHD risk factors were defined as total cholesterol ≥240 mg/dL (≥6.22 mmol/L), systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, smoking, and diabetes. Study subjects were stratified by age and sex. Among subjects dying of CHD, exposure to at least one risk factor ranged from 87 percent (for men aged 40 to 59 in the MRFIT trial) to 100 percent (for women aged 18 to 39 years in the Framingham Heart Study).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another report, based upon 14 randomized clinical trials of CHD, included more than 120,000 subjects with ST elevation MI, non-ST elevation acute coronary syndrome, or percutaneous coronary intervention [
         <a href="#rid45">
          45
         </a>
         ]. Risk factors were defined by information collected at the time of study enrollment, including smoking, diabetes, hypertension, and hyperlipidemia. At least one of these four risk factors was present in 85 percent of women and 81 percent of men. When stratified by age, the lowest prevalence of at least one risk factor was seen among subjects &gt;75 years old (77 percent of women and 65 percent of men).
        </p>
        <p>
        </p>
        <p>
         Several metrics for risk factors have been associated with greater cardiovascular disease (CVD) risk: mean levels, median levels, time spent at a high risk factor level, and increased variability in a specific metric over time. This has been reported for the risk factors blood pressure, cholesterol levels, and body weight, among others [
         <a href="#rid47">
          47-51
         </a>
         ]. Patients who are not very compliant with their treatments often have greater variability in risk factor measurements, and measurement error is often much greater at high values. Compounding the issue for heart disease is that very low-weight persons may experience greater risk for recurrent heart disease.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Risk factor prevalence
         </span>
         <span class="headingEndMark">
          —
         </span>
         An exact estimate of the prevalence of CVD risk factors remains elusive, but the prevalence of identified risk factors has changed over time with increased awareness and changes in diet and lifestyle. A comparison of results from sequential reports from the National Health and Nutrition Examination Survey (NHANES) has shown that the prevalence of obesity (body mass index [BMI] ≥30 kg/m2) increased dramatically in the United States between 1960 and 2000 (15 to 30 percent) [
         <a href="#rid52">
          52
         </a>
         ]. Not surprisingly, there was an associated increase in diagnosed diabetes (1.8 to 5.0 percent) that was most prominent in obese subjects (2.9 to 10.1 percent). (See
         <a class="local">
          'Obesity'
         </a>
         below.)
        </p>
        <p>
         By contrast, a number of other major cardiovascular risk factors declined substantially between 1960 and 2000 [
         <a href="#rid52">
          52
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum total cholesterol ≥240 mg/dL (6.2 mmol/L) – 34 to 17 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypertension (blood pressure ≥140/≥90 mmHg) – 31 to 15 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Smoking – 39 to 26 percent
        </p>
        <p>
        </p>
        <p>
         These changes occurred in all weight groups, including obese individuals, and were associated with increases in the use of lipid-lowering drugs and antihypertensive medications. (See
         <a class="medical medical_review" href="/z/d/html/5370.html" rel="external">
          "Overweight and obesity in adults: Health consequences", section on 'Trends in cardiovascular risk factors'
         </a>
         .)
        </p>
        <p>
         The presence of established risk factors is associated with CVD, and the achievement and maintenance of good health is being emphasized in programs from the American Heart Association (AHA) that promote seven ideal cardiovascular health metrics (“Life’s Simple 7”), including [
         <a href="#rid53">
          53
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Not smoking
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Being physically active
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Having a normal blood pressure
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Having a normal blood glucose level
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Having a normal total cholesterol level
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Being normal weight
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Eating a healthy diet
        </p>
        <p>
        </p>
        <p>
         Numerous studies have consistently shown CVD morbidity and mortality benefits of achieving greater numbers of ideal cardiovascular health metrics, with relative risk reductions approaching 75 percent in persons achieving all seven metrics [
         <a href="#rid54">
          54-61
         </a>
         ]. In a 2018 systemic review and meta-analysis which included 210,443 persons from 12 cohort studies, persons achieving between five and seven ideal cardiovascular health metrics had the greatest reduction in incident CVD (hazard ratio [HR] 0.28 compared with persons achieving between zero and two metrics; 95% CI 0.23-0.33), while persons achieving three and four metrics also derived a smaller but significant benefit (HR 0.53 compared with persons achieving between zero and two metrics; 95% CI 0.47-0.59) [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
         Risk factor prevalence in developing nations has long been unknown and/or underrepresented in the literature. Among 46,239 Chinese adults age 20 or older (40 percent male) recruited in 2007 and 2008 as a nationally representative cohort, the overall prevalence of CVD was low (1.8 and 1.1 percent in males and females, respectively) [
         <a href="#rid63">
          63
         </a>
         ]. The prevalence of traditional CVD risk factors was much higher:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Overweight or obese – 36.7 and 29.8 percent in males and females, respectively
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypertension – 30.1 and 24.8 percent in males and females, respectively
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dyslipidemia – 64 and 67.4 percent in males and females, respectively
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperglycemia – 26.7 and 23.6 percent in males and females, respectively
        </p>
        <p>
        </p>
        <p>
         After adjusting for age and sex, the odds of CVD increased with the number of risk factors present (OR 2.4, 4.2, 4.9, and 7.2 for 1, 2, 3, and 4 or more risk factors, respectively, compared with no risk factors) [
         <a href="#rid63">
          63
         </a>
         ]. These data suggest that, in the absence of effective lifestyle and medical interventions, there is likely to be a significant increase in the incidence and prevalence of CVD in China in the future.
        </p>
        <p class="headingAnchor" id="H4873728">
         <span class="h2">
          Risk factors in childhood
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cardiovascular risk factors are identifiable in childhood and may be predictive of the subsequent development of CHD [
         <a href="#rid64">
          64-66
         </a>
         ]. The identification of children with risk factors for CVD and the development of atherosclerosis in children are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/16975.html" rel="external">
          "Pediatric prevention of adult cardiovascular disease: Promoting a healthy lifestyle and identifying at-risk children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5781.html" rel="external">
          "Overview of risk factors for development of atherosclerosis and early cardiovascular disease in childhood"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Age and sex
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cardiovascular risk factors promote CVD in either biological sex at all ages but with different relative importance.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diabetes and a low HDL-cholesterol/total cholesterol ratio operate with greater power in women [
         <a href="#rid67">
          67,68
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1542.html" rel="external">
          "Prevalence of and risk factors for coronary heart disease in patients with diabetes mellitus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The incidence of an MI is increased sixfold in women and threefold in men who smoke at least 20 cigarettes per day compared with subjects who never smoked [
         <a href="#rid69">
          69,70
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1504.html" rel="external">
          "Cardiovascular risk of smoking and benefits of smoking cessation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Systolic blood pressure and isolated systolic hypertension are major CHD risk factors in males and females at all ages [
         <a href="#rid41">
          41
         </a>
         ]. The Framingham study found that the relative importance of systolic, diastolic, and pulse pressure (the difference between the systolic and diastolic blood pressures) changes with age [
         <a href="#rid71">
          71
         </a>
         ]. In patients &lt;50 years of age, diastolic blood pressure was the strongest predictor of CHD risk; in those 50 to 59 years of age, all three blood pressure indices were comparable predictors of CHD risk, while in those ≥60 years of age, pulse pressure was the strongest predictor. (See
         <a class="local">
          'Hypertension'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/3850.html" rel="external">
          "Cardiovascular risks of hypertension"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some risk factors, such as dyslipidemia, impaired glucose tolerance, and elevated fibrinogen have a diminished impact with advancing age, but a lower relative risk is offset by the high absolute risk in older adults [
         <a href="#rid72">
          72,73
         </a>
         ]. Thus, all of the major risk factors continue to be relevant in older persons.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obesity or weight gain promotes or aggravates most of the atherogenic risk factors and physical inactivity worsens some of them, predisposing subjects of all ages to CHD events [
         <a href="#rid74">
          74-76
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5370.html" rel="external">
          "Overweight and obesity in adults: Health consequences"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5379.html" rel="external">
          "Obesity in adults: Role of physical activity and exercise"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Age alone also appears to contribute to the development of CVD. In a cohort of more than 3.6 million individuals age 40 years or older who underwent self-referred screening for CVD (ankle brachial index, carotid duplex ultrasound, and abdominal ultrasound), the prevalence of any vascular disease increased significantly with each decade of life [
         <a href="#rid77">
          77
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         2 percent in 40- to 50-year-olds
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         3.5 percent in 51- to 60-year-olds
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         7.1 percent in 61- to 70-year-olds
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         13 percent in 71- to 80-year-olds
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         22.3 percent in 81- to 90-year-olds
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         32.5 percent in 91- to 100-year-olds
        </p>
        <p>
        </p>
        <p>
         After adjusting for traditional risk factors, each additional decade of life was associated with an approximate doubling of the risk of vascular disease (ORs per decade of life were 2.14, 1.80, and 2.33 for peripheral arterial disease, carotid stenosis, and abdominal aortic aneurysm, respectively).
        </p>
        <p>
         Male sex alone may contribute to the risk of CHD, although the potential mechanisms for such risk are not well understood. Several population studies have identified male sex as a risk factor for higher rates of CHD and CHD-related mortality [
         <a href="#rid78">
          78-80
         </a>
         ]. Among 31,000 patients from the ONTARGET and TRANSCEND study populations (9378 females, 22,168 males) who were followed for an average of 56 months, females had approximately 20 percent lower risk than males for all major cardiovascular endpoints including cardiovascular death (adjusted RR 0.83, 95% CI 0.75-0.92), MI (adjusted RR 0.78, 95% CI 0.68-0.89), and a combined endpoint of death, MI, stroke, and heart failure hospitalization (adjusted RR 0.81, 95% CI 0.76-0.87) [
         <a href="#rid80">
          80
         </a>
         ]. In premenopausal women, serious manifestations of coronary disease, such as MI and sudden death, are relatively rare. After menopause, the incidence and severity of coronary disease increases abruptly, with rates three times those of women the same age who remain premenopausal [
         <a href="#rid81">
          81
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1468.html" rel="external">
          "Overview of atherosclerotic cardiovascular risk factors in females"
         </a>
         .)
        </p>
        <p>
         The risk of CHD in men has been associated with variations in the Y chromosome. Among 3233 biologically unrelated British men who underwent genotyping of their Y chromosome, with 13 apparent ancient lineages (haplogroups) identified based on the genotype results, those descendent from one particular haplogroup (haplogroup I, almost entirely unique to Europeans) had significantly more CHD than men from other haplogroups (OR 1.56, 95% CI 1.24-1.97) [
         <a href="#rid82">
          82
         </a>
         ]. These results suggest that differences in CHD risk within the male sex are associated with inherited variations in sex chromosomes, which may contribute to the importance of family history as a risk factor for CHD. (See
         <a class="local">
          'Family history'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/16307.html" rel="external">
          "Overview of possible risk factors for cardiovascular disease", section on 'Genetic markers'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Family history
         </span>
         <span class="headingEndMark">
          —
         </span>
         Family history is an independent risk factor for CHD, particularly among younger individuals with a family history of premature disease [
         <a href="#rid83">
          83-89
         </a>
         ]. There is general agreement that development of atherosclerotic CVD or death from CVD in a first-degree relative (ie, biological parent or sibling) prior to age 55 (males) or 65 (females) denotes a significant family history, although the definition of what constitutes a family history of premature atherosclerosis has been somewhat variable across studies [
         <a href="#rid90">
          90-92
         </a>
         ]. A wider definition of a significant family history of CVD might also include CVD in a first-degree relative of any age (ie, not necessarily premature) or other manifestations of atherosclerosis beyond MI or CHD death, including stroke or transient ischemic attack, CHD requiring revascularization in the absence of MI, peripheral artery disease, and abdominal aortic aneurysm  (
         <a class="graphic graphic_table graphicRef71096" href="/z/d/graphic/71096.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid92">
          92
         </a>
         ]. One study has suggested that compared with a family history of premature CVD or a more detailed family history, asking a single question (does any first-degree relative have CVD, at any age?) was as helpful in identifying an increased risk of CVD [
         <a href="#rid92">
          92
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/50.html" rel="external">
          "Coronary artery disease and myocardial infarction in young people"
         </a>
         .)
        </p>
        <p>
         Using data from the 2011 to 2014 NHANES survey, the 2017 AHA heart disease and stroke statistics reported that 12.2 percent of adults have a biological parent or sibling with heart attack or angina before age 50 years [
         <a href="#rid93">
          93
         </a>
         ]. The importance of family history has been shown in several large cohort studies (Physician's Health Study, Women's Health Study, Reykjavik Cohort Study, Framingham Offspring Study, INTERHEART Study, Cooper Center Longitudinal Study, Danish national population database) that collectively followed over 163,000 patients, and all showed that a positive family history is associated with greater risk of developing CHD [
         <a href="#rid83">
          83,84,86,87,94-97
         </a>
         ]. The risk of developing CHD in the presence of a positive family history has ranged from 15 to 100 percent in various cohorts, with most cohorts showing a 30 to 60 percent increase [
         <a href="#rid92">
          92
         </a>
         ].
        </p>
        <p>
         The importance of a family history of premature CVD death appears to be magnified in families with multiple premature deaths [
         <a href="#rid98">
          98-100
         </a>
         ]. Using data from the Danish Family Relations Database (3,985,301 persons born between 1950 and 2008 followed for nearly 90 million person-years), persons from families with two or more premature cardiovascular deaths among first-degree relatives had a threefold greater risk of developing CVD before age 50 (incidence risk ratio 3.30, 95% CI 2.77-3.94) [
         <a href="#rid98">
          98
         </a>
         ]. Similar findings have been noted among 185,810 cases of hospitalization or death due to CHD in the Swedish Multi-Generation Registry, in which the risk of hospitalization or death due to CHD was increased six- to sevenfold in persons with two or three siblings with CHD [
         <a href="#rid99">
          99
         </a>
         ].
        </p>
        <p>
         Despite multiple studies showing that family history of CHD in a first-degree relative increases one's risk of developing CHD, the incremental predictive value of adding family history to an established risk score appears to be small, ranging from 2 to 5 percent upward reclassification of risk [
         <a href="#rid88">
          88,101
         </a>
         ]. In the EPIC-Norfolk prospective cohort of 22,841 patients (45 percent male) aged 40 to 79 years who were followed for a mean of 10.9 years, a family history of CHD in a first-degree relative was associated with increased risk of future CHD independent of the Framingham Risk Score (FRS) estimate (adjusted HR 1.74, 95% CI 1.56-1.95) [
         <a href="#rid88">
          88
         </a>
         ]. Despite this significantly increased risk, the addition of family history to the FRS estimate resulted in minimal reclassification of patients into different risk groups (only 2 percent of patients deemed intermediate risk by FRS were reclassified to high risk because of family history). (See
         <a class="medical medical_review" href="/z/d/html/114029.html" rel="external">
          "Cardiovascular disease risk assessment for primary prevention: Risk calculators"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Reliability of self-reported family history
         </span>
         <span class="headingEndMark">
          —
         </span>
         The accuracy and reliability of a self-reported family history may be difficult to ascertain. A 2009 report from the National Institutes of Health reviewed the accuracy of self-reported family history of several common disease states (asthma and allergies, diabetes mellitus, major depression and mood disorders, stroke, CVD, and five common types of cancer) [
         <a href="#rid90">
          90
         </a>
         ]. The probability that an unaffected family member was correctly identified as disease-free was high (90 to 95 percent), but for family members with one of the diseases, the probability that they were correctly identified as having the disease was generally lower and far more variable (as low as 6 percent correct identified as having a mood disorder, up to 95 percent correct for some types of cancer). Generally, patients more accurately identified healthy family members as being healthy and were less accurate in correctly identifying family members with specific diseases.
        </p>
        <p>
         The reliability of a self-reported family history of CHD or of risk factors for CHD was explored in an analysis from the Framingham Offspring Study [
         <a href="#rid102">
          102
         </a>
         ]. A group of 1628 children of study participants completed a questionnaire regarding parental medical history. The following findings were noted:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The predictive value of an affirmative statement was above 75 percent for family histories of hypertension, diabetes, and hypercholesterolemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For cardiac death the positive predictive value was only 66 percent for fathers and 47 percent for mothers.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The predictive value of a negative statement was above 90 percent for family history of cardiac death or for diabetes, but below 60 percent for family history of hypertension or hypercholesterolemia.
        </p>
        <p>
        </p>
        <p>
         These findings concerning validated and self-reported family history from Framingham suggest that there is some value in obtaining family history information, but that self-reported information might not be accurate. They also suggest that the additional contribution of family history to CHD risk estimation after inclusion of other traditional risk factors is relatively modest.
        </p>
        <p class="headingAnchor" id="H4874043">
         <span class="h2">
          Hypertension
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypertension is a well-established risk factor for adverse cardiovascular outcomes, including mortality from CHD and stroke [
         <a href="#rid103">
          103,104
         </a>
         ]. The lifetime risk of developing CVD is significantly higher among patients with hypertension  (
         <a class="graphic graphic_table graphicRef115008" href="/z/d/graphic/115008.html" rel="external">
          table 5
         </a>
         ). In a cohort of over 1.25 million patients aged 30 years or older without baseline CVD, including 20 percent with baseline treated hypertension, patients with baseline hypertension had a 63.3 percent lifetime risk of developing CVD compared with a 46.1 percent risk for those with normal baseline blood pressure [
         <a href="#rid5">
          5
         </a>
         ]. In a separate study from the INTERHEART group, hypertension accounted for 18 percent of the population-attributable risk of a first MI [
         <a href="#rid26">
          26
         </a>
         ]. Greater variations in blood pressure from one visit to the next may also be associated with greater risk of CVD and mortality [
         <a href="#rid105">
          105
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3850.html" rel="external">
          "Cardiovascular risks of hypertension"
         </a>
         .)
        </p>
        <p>
         The determination of what blood pressure constitutes hypertension has long been the subject of debate, with various committees and professional societies publishing statements or guidelines attempting to define categories of hypertension [
         <a href="#rid41">
          41,106
         </a>
         ]. An extensive discussion of the definition of hypertension and treatment recommendations for various patient groups is presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3852.html" rel="external">
          "Overview of hypertension in adults", section on 'Definitions'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3861.html" rel="external">
          "Goal blood pressure in adults with hypertension"
         </a>
         .)
        </p>
        <p>
         Although blood pressure at the time of risk assessment (current blood pressure) is typically used in most prediction algorithms, this does not accurately reflect an individual's past blood pressure experience. Two analyses demonstrate the importance of inclusion of past blood pressure into risk prediction models since the duration as well as the degree of hypertension are both risk factors. This issue is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3850.html" rel="external">
          "Cardiovascular risks of hypertension", section on 'Current risk versus prior risk'
         </a>
         .)
        </p>
        <p>
         Ambulatory blood pressure measurements may be more predictive in patients with office or white coat hypertension. (See
         <a class="medical medical_review" href="/z/d/html/3820.html" rel="external">
          "Out-of-office blood pressure measurement: Ambulatory and self-measured blood pressure monitoring"
         </a>
         .)
        </p>
        <p>
         A separate issue is the goal blood pressure in patients who already have or are at high risk for CVD. This issue is discussed in great detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3850.html" rel="external">
          "Cardiovascular risks of hypertension"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3861.html" rel="external">
          "Goal blood pressure in adults with hypertension"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Lipids and lipoproteins
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lipids, principally cholesterol and triglycerides, are the water insoluble compounds that require larger protein-containing complexes called lipoproteins to transport them in blood. The protein components of the lipoprotein are known as apolipoproteins or apoproteins. (See
         <a class="medical medical_review" href="/z/d/html/4565.html" rel="external">
          "Lipoprotein classification, metabolism, and role in atherosclerosis"
         </a>
         .)
        </p>
        <p>
         The determination of what cholesterol level constitutes dyslipidemia has long been the subject of debate, with professional societies publishing statements or guidelines attempting to delineate risk levels and when to consider drug therapy for dyslipidemia [
         <a href="#rid107">
          107
         </a>
         ].
        </p>
        <p>
         The prevalence of dyslipidemia is increased in patients with premature CHD, being as high as 75 to 85 percent compared with approximately 40 to 48 percent in age-matched controls without CHD [
         <a href="#rid85">
          85,108
         </a>
         ]. In the INTERHEART study, dyslipidemia (defined as a raised apo B to apo A-1 ratio) accounted for 49 percent of the population-attributable risk of a first MI [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         Disturbances in lipoprotein metabolism are often familial. As an example, 54 percent of all patients and 70 percent of those with a lipid abnormality in one reported series had a familial lipid disorder [
         <a href="#rid108">
          108
         </a>
         ]. The most common familial disturbances were Lp(a) excess (alone or with other dyslipidemia), hypertriglyceridemia with hypoalphalipoproteinemia, and combined hyperlipidemia. Conversely, patients with favorable genetic profiles that result in lifelong exposure to lower low-density lipoprotein (LDL) cholesterol levels have been shown to be at decreased risk of MI, coronary revascularization, or death from CHD [
         <a href="#rid109">
          109
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4567.html" rel="external">
          "Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia"
         </a>
         .)
        </p>
        <p>
         Evidence for the pathogenic importance of serum cholesterol has largely come from randomized trials which showed that reductions in total and LDL cholesterol levels (almost entirely with statins) reduce coronary events and mortality when given for primary and secondary prevention [
         <a href="#rid110">
          110-112
         </a>
         ]. Factors other than LDL cholesterol lowering also may contribute to the observed benefit from statin therapy. (See
         <a class="medical medical_review" href="/z/d/html/4546.html" rel="external">
          "Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">
          "Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"
         </a>
         .)
        </p>
        <p>
         Recommendations for the treatment of hypercholesterolemia are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">
          "Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">
          "Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"
         </a>
         .)
        </p>
        <p>
         The following lipid and lipoprotein abnormalities are associated with increased CHD risk. The supportive data are presented elsewhere as noted:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elevated total cholesterol  (
         <a class="graphic graphic_figure graphicRef60146" href="/z/d/graphic/60146.html" rel="external">
          figure 2
         </a>
         ) and elevated LDL cholesterol (see
         <a class="medical medical_review" href="/z/d/html/4553.html" rel="external">
          "Screening for lipid disorders in adults", section on 'Rationale for screening'
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low HDL cholesterol (see
         <a class="medical medical_review" href="/z/d/html/4560.html" rel="external">
          "HDL cholesterol: Clinical aspects of abnormal values", section on 'Low HDL cholesterol as an ASCVD risk factor'
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypertriglyceridemia (see
         <a class="medical medical_review" href="/z/d/html/4570.html" rel="external">
          "Hypertriglyceridemia in adults: Management"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased non-HDL cholesterol (see
         <a class="medical medical_review" href="/z/d/html/4553.html" rel="external">
          "Screening for lipid disorders in adults", section on 'Choice of tests'
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased Lp(a) (see
         <a class="medical medical_review" href="/z/d/html/4566.html" rel="external">
          "Lipoprotein(a)"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased apolipoprotein C-III (see
         <a class="medical medical_review" href="/z/d/html/4565.html" rel="external">
          "Lipoprotein classification, metabolism, and role in atherosclerosis"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Small, dense LDL particles (see
         <a class="medical medical_review" href="/z/d/html/4567.html" rel="external">
          "Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia", section on 'Small dense LDL (LDL phenotype B)'
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Different genotypes of apolipoprotein E (apoE) influence cholesterol and triglyceride levels as well as the risk of CHD (see
         <a class="medical medical_review" href="/z/d/html/4567.html" rel="external">
          "Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia", section on 'Genetics'
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         LDL levels in the normal range correlate with subclinical atherosclerosis in patients without traditional CHD risk factors, suggesting a continuous relationship with no clear threshold [
         <a href="#rid113">
          113
         </a>
         ].
        </p>
        <p>
         The abnormalities discussed above require measurement of lipids or lipoproteins. Proton nuclear magnetic resonance (NMR) spectroscopy of lipoprotein particles has been proposed as an alternative method for predicting CVD risk [
         <a href="#rid114">
          114
         </a>
         ]. In a study of over 27,000 women, this technique was comparable in predictive accuracy to, but not better than, standard measurement of lipids or apolipoproteins [
         <a href="#rid114">
          114
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1057612543">
         <span class="h2">
          Diabetes mellitus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Insulin resistance, hyperinsulinemia, and elevated blood glucose are associated with atherosclerotic CVD [
         <a href="#rid115">
          115-122
         </a>
         ]. In the INTERHEART study, diabetes accounted for 10 percent of the population-attributable risk of a first MI [
         <a href="#rid26">
          26
         </a>
         ]. The all-cause mortality risk associated with diabetes has been compared with the all-cause mortality risk associated with a prior MI [
         <a href="#rid123">
          123
         </a>
         ].
        </p>
        <p>
         In addition to the importance of diabetes as a risk factor, diabetics have a greater burden of other atherogenic risk factors than nondiabetics, including hypertension, obesity, increased total to HDL cholesterol ratio, hypertriglyceridemia, and elevated plasma fibrinogen. The CHD risk in diabetics varies widely with the intensity of these risk factors.
        </p>
        <p>
         Guidelines published by the National Cholesterol Education Program and the sixth Joint National Committee have provided a framework to treat coronary risk factors aggressively in diabetics [
         <a href="#rid39">
          39,103
         </a>
         ]. There is compelling evidence of the value of aggressive therapy of serum cholesterol and hypertension in patients with diabetes [
         <a href="#rid124">
          124-126
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3829.html" rel="external">
          "Treatment of hypertension in patients with diabetes mellitus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">
          "Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1057612549">
         <span class="h3">
          Hyperglycemia without overt diabetes mellitus
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is good evidence from observational studies that higher levels of blood glucose and glycated hemoglobin correlate with cardiovascular risk in patients with and without diabetes at baseline. Data on this are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1542.html" rel="external">
          "Prevalence of and risk factors for coronary heart disease in patients with diabetes mellitus", section on 'CHD before diabetes'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1542.html" rel="external">
          "Prevalence of and risk factors for coronary heart disease in patients with diabetes mellitus", section on 'Hyperglycemia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1057612555">
         <span class="h2">
          Chronic kidney disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The increased CHD risk in patients with end-stage kidney disease has been well described, but there is now clear evidence that mild to moderate kidney dysfunction is also associated with a substantial increase in CHD risk [
         <a href="#rid127">
          127
         </a>
         ]. Practice guidelines from the National Kidney Foundation in 2002 and the American College of Cardiology (ACC)/American Heart Association (AHA) task force in 2004 recommended that chronic kidney disease (CKD) be considered a CHD risk equivalent [
         <a href="#rid128">
          128,129
         </a>
         ].
        </p>
        <p>
         Patients with CKD who undergo stress testing have worse outcomes, regardless of the outcome, when compared with patients without CKD. In a study of 1652 patients who underwent stress radionuclide myocardial perfusion imaging (rMPI), among whom CKD (defined as estimated globular filtration rate &lt;60 mL/minute/1.73 m
         <sup>
          2
         </sup>
         ) was present in 36 percent of subjects, patients with CKD had significantly worse prognosis for similar rMPI result compared with patients without CKD [
         <a href="#rid130">
          130
         </a>
         ]. With CKD and a normal test, the annual cardiac death rate was 2.7 percent; with no CKD and a normal test, the annual cardiac death rate was significantly lower (0.8 percent). With CKD and ischemia, the annual cardiac death rate was 11 percent; with no CKD and ischemia, the annual cardiac death rate was significantly lower (4.5 percent).
        </p>
        <p>
         The data supporting this conclusion are presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7190.html" rel="external">
          "Chronic kidney disease and coronary heart disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Lifestyle factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of lifestyle factors impact the risk of CVD:
        </p>
        <p class="headingAnchor" id="H4872547">
         <span class="h3">
          Cigarette smoking
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cigarette smoking is an important and reversible risk factor for CHD. In 2016, approximately 15.5 percent of United States adults age ≥18 years were smoking [
         <a href="#rid4">
          4
         </a>
         ]. The incidence of a MI is increased sixfold in women and threefold in men who smoke at least 20 cigarettes per day compared with subjects who never smoked [
         <a href="#rid69">
          69,70
         </a>
         ]. The risk of MI is proportional to tobacco consumption in both males and females and is higher in inhalers compared with non-inhalers [
         <a href="#rid70">
          70
         </a>
         ]. In the INTERHEART study, smoking accounted for 36 percent of the population-attributable risk of a first MI [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         Conversely, the risk of recurrent infarction in a study of smokers who had an MI fell by 50 percent within one year of smoking cessation and normalized to that of nonsmokers within two years [
         <a href="#rid131">
          131
         </a>
         ]. The benefits of smoking cessation are seen regardless of how long or how much the patient has previously smoked. (See
         <a class="medical medical_review" href="/z/d/html/1504.html" rel="external">
          "Cardiovascular risk of smoking and benefits of smoking cessation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4872729">
         <span class="h3">
          Diet
         </span>
         <span class="headingEndMark">
          —
         </span>
         Aspects of diet that have been evaluated for CHD risk include the glycemic index (GI), sugar sweetened beverages, fruits and vegetables, meat, trans fatty acids, fiber, coffee, and low-cholesterol diets.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dietary factors that may increase risk
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          High glycemic index
         </strong>
         – Diets containing foods with a high GI or glycemic load (GL) may contribute to the risk of CHD  (
         <a class="graphic graphic_table graphicRef71978" href="/z/d/graphic/71978.html" rel="external">
          table 6
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Consumption of sugar sweetened beverages
         </strong>
         – Consumption of sugar sweetened beverages has been associated with a higher risk of CHD [
         <a href="#rid132">
          132
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Low consumption of fruits and vegetables
         </strong>
         – There is growing evidence that greater fruit and vegetable consumption is inversely related to the risk of CVD.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         High serum concentrations of enterolactone, a putative biomarker of a diet high in fiber and vegetables, have been inversely correlated with the risk of acute coronary events and with CHD mortality. (See
         <a class="medical medical_review" href="/z/d/html/5364.html" rel="external">
          "Healthy diet in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7573.html" rel="external">
          "Overview of primary prevention of cardiovascular disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          High consumption of red meat
         </strong>
         – Greater intake of red meat has been associated with higher risks of CVD.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          High consumption of trans fatty acids
         </strong>
         – Several observational studies have linked the consumption of trans fatty acids, or foods that contain them, with adverse cardiovascular outcomes  (
         <a class="graphic graphic_table graphicRef75539" href="/z/d/graphic/75539.html" rel="external">
          table 7
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4555.html" rel="external">
          "Dietary fat", section on 'Trans fatty acids'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Low consumption of Fiber
         </strong>
         – Low fiber intake is inversely related to risk of CHD. It is also associated with development of cardiovascular risk factors including hypertension, diabetes mellitus, and elevated lipid levels.  (
         <a class="graphic graphic_table graphicRef82094" href="/z/d/graphic/82094.html" rel="external">
          table 8
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dietary factors of uncertain effect
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Coffee
         </strong>
         – Coffee consumption, both caffeinated and non-caffeinated, appears to have a neutral effect on the development of CVD. (See
         <a class="medical medical_review" href="/z/d/html/5369.html" rel="external">
          "Benefits and risks of caffeine and caffeinated beverages"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1553.html" rel="external">
          "Cardiovascular effects of caffeine and caffeinated beverages"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Low-cholesterol diet
         </strong>
         – The relationship between dietary cholesterol and development of CVD is unclear due to observational studies with mixed results. However, the 2020 Dietary Guidelines for Americans suggest maintaining an overall healthy eating pattern and consuming as little dietary cholesterol as possible [
         <a href="#rid133">
          133
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h3">
          Exercise
         </span>
         <span class="headingEndMark">
          —
         </span>
         Exercise of even moderate degree has a protective effect against CHD and all-cause mortality [
         <a href="#rid26">
          26,76,134-137
         </a>
         ]. Exercise may have a variety of beneficial effects including an elevation in serum HDL cholesterol, a reduction in blood pressure, less insulin resistance, and weight loss. In addition to the amount of exercise performed, the degree of cardiovascular fitness (a measure of physical activity), as determined by duration of exercise and maximal oxygen uptake on a treadmill, is also associated with a reduction in CHD risk and overall cardiovascular mortality [
         <a href="#rid138">
          138-148
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Men who engaged in moderately vigorous sports activity have been reported to have a 23 percent lower risk of death than those who were less active [
         <a href="#rid134">
          134
         </a>
         ]. Persons with mild to moderate levels of physical activity as part of their occupation appear to have lower risk of MI compared with sedentary workers [
         <a href="#rid145">
          145
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the INTERHEART study, lack of regular physical activity accounted for 12 percent of the population-attributable risk of a first MI [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiovascular fitness has been assessed in several studies [
         <a href="#rid142">
          142,143,146-148
         </a>
         ]. In a prospective study of 6213 men referred for exercise testing who were followed for a mean of 6.2 years [
         <a href="#rid142">
          142
         </a>
         ], peak exercise capacity, measured in metabolic equivalents (METs), was a stronger predictor of mortality than other established cardiovascular risk factors among men with and without CVD. In a separate study of 11,190 persons deemed "low-risk" by FRS and without diabetes mellitus who underwent treadmill exercise testing and were followed for an average of 27 years, all-cause mortality was significantly higher among individuals in the lowest quintile of exercise capacity at baseline (15 versus 6 percent mortality in the highest quintile) [
         <a href="#rid143">
          143
         </a>
         ]. In a study of cardiorespiratory fitness in 5107 man (mean age 48.8 years) without known CVD who were followed for 46 years, high cardiorespiratory fitness in the fifth decade of life was associated with mortality benefits extending for over four decades [
         <a href="#rid147">
          147
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Resistance training appears to have a beneficial impact on several risk factors for cardiovascular disease. These include lowering blood pressure, reducing fasting serum glucose concentrations, improving insulin sensitivity and dyslipidemia, decreasing waist circumference, and improving body composition [
         <a href="#rid149">
          149-156
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/115880.html" rel="external">
          "Strength training for health in adults: Terminology, principles, benefits, and risks"
         </a>
         .)
        </p>
        <p>
         The AHA prepared a listing of the most effective strategies to promote exercise, as well as a healthy diet, based on a systematic review of studies published in English between 1999 and 2009  (
         <a class="graphic graphic_table graphicRef59899" href="/z/d/graphic/59899.html" rel="external">
          table 9
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1510.html" rel="external">
          "Exercise and fitness in the prevention of atherosclerotic cardiovascular disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2786.html" rel="external">
          "The benefits and risks of aerobic exercise"
         </a>
         .)
        </p>
        <p>
         In 2018, the US Department of Health and Human Services published guidelines for physical activity in children and adults [
         <a href="#rid157">
          157
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/120020.html" rel="external">
          "Exercise prescription and guidance for adults", section on 'Prescribing an exercise program'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4872925">
         <span class="h3">
          Alcohol
         </span>
         <span class="headingEndMark">
          —
         </span>
         Epidemiologic data indicate that moderate alcohol intake has a protective effect on CHD. (See
         <a class="medical medical_review" href="/z/d/html/2784.html" rel="external">
          "Cardiovascular benefits and risks of moderate alcohol consumption"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4486076">
         <span class="h3">
          Obesity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Obesity, defined as a BMI greater than 30, is a highly prevalent condition, particularly in developed countries, with estimates that 35 percent of the population of the United States in 2011 to 2012 was obese [
         <a href="#rid158">
          158
         </a>
         ]. Obesity is associated with a number of risk factors for atherosclerosis, CVD, and cardiovascular mortality, including hypertension, insulin resistance and glucose intolerance, hypertriglyceridemia, reduced HDL cholesterol, and low levels of adiponectin [
         <a href="#rid159">
          159-162
         </a>
         ]. However, in an analysis of data from 4780 adults in the Framingham Offspring Study, obesity as measured by BMI significantly and independently predicted the occurrence of CHD and cerebrovascular disease after adjusting for traditional risk factors [
         <a href="#rid163">
          163
         </a>
         ]. Additionally, there is a continuous linear relationship between higher BMI and greater risk of CVD [
         <a href="#rid164">
          164,165
         </a>
         ]. These relationships are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1529.html" rel="external">
          "Obesity: Association with cardiovascular disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5370.html" rel="external">
          "Overweight and obesity in adults: Health consequences"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5375.html" rel="external">
          "Obesity in adults: Dietary therapy"
         </a>
         .)
        </p>
        <p>
         In addition to the risk associated with obesity, patients with more significant fluctuations in body weight (ie, cycles of weight gain and weight loss) appear to have an increased risk of future CVD events. Among 9509 patients with established CVD and LDL cholesterol below 130 mg/dL (3.4 mmol/L) who participated in the randomized Treating to New Targets trial (randomized to 10 mg or 80 mg of daily
         <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">
          atorvastatin
         </a>
         ), post hoc analysis was performed to assess the impact of fluctuations in body weight on the composite outcome of any CHD event (combination of death from CHD, nonfatal MI, resuscitated sudden cardiac arrest, revascularization, and angina) [
         <a href="#rid51">
          51
         </a>
         ]. For each standard deviation increase in body weight fluctuation (approximately 1.5 to 1.9 kg deviation from baseline), there was a significant increase in the hazard of any CHD event (HR 1.04; 95% CI 1.01-1.07). Patients in the highest quintile of weight fluctuation (mean variability of 3.9 kg) had significantly higher risks of any CHD event (64 percent higher), any CVD event (85 percent higher), and total mortality (124 percent higher). These data suggest that frequent cycles of weight gain and weight loss are associated with an increased risk of CHD and CVD events, with the greatest magnitude of risk among those who were overweight or obese at baseline.
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h3">
          Psychosocial factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Psychosocial factors may contribute to the early development of atherosclerosis as well as to the acute precipitation of MI and sudden cardiac death. The link between psychologic stress and atherosclerosis may be both direct, via damage of the endothelium, and indirect, via aggravation of traditional risk factors such as smoking, hypertension, and lipid metabolism. Depression, anger, stress, and other factors have been correlated with cardiovascular outcomes. (See
         <a class="medical medical_review" href="/z/d/html/4862.html" rel="external">
          "Psychosocial factors in coronary and cerebral vascular disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4854.html" rel="external">
          "Psychosocial factors in acute coronary syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1235972458">
         <span class="h3">
          Sex differences
         </span>
         <span class="headingEndMark">
          —
         </span>
         The importance of some metabolic, behavioral, and psychosocial risk factors may differ by sex. Data from the Prospective Urban Rural Epidemiological (PURE) study, which followed adults from 21 high-, middle-, and low-income countries for 10 years, showed that LDL cholesterol and non-HDL cholesterol levels generally rose with age in women and after age 55 years were typically greater in women than in men, which has been attributable to menopause. The authors also reported that high non-HDL cholesterol was associated with a higher risk of CVD in men compared with women (HR 1.28, 95% CI 1.19-1.39 versus HR 1.11, 95% CI 1.01-1.21) [
         <a href="#rid166">
          166
         </a>
         ]. Symptoms of depression were associated with a higher risk of CVD in men compared with women (HR 1.42, 95% CI, 1.25-1.60 versus HR 1.09, 95% CI 0.98-1.21). Among behavioral factors of smoking, alcohol consumption, diet, and physical activity, a lower-quality diet was more strongly associated with major CVD in women than men (HR 1.17, 95% CI 1.08-1.26 versus HR 1.07, 95% CI 0.99-1.15). The total population attributable fraction of CVD associated with lifestyle factors were greater in men than in women (15.7 versus 8.4 percent); this was largely due to the greater prevalence of smoking to CVD risk in men compared with women (10.7 versus 1.3 percent).
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h2">
          Inflammation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Numerous markers of inflammation markers have been reported to be associated with increased risk of CVD [
         <a href="#rid167">
          167,168
         </a>
         ]. C-reactive protein (CRP) is both the most extensively studied marker of inflammation and the marker most widely used in clinical practice. Its precise role in the assessment of cardiovascular risk continues to evolve. While the precise role of CRP remains uncertain, epidemiologic studies have suggested that interleukin (IL)-6 has a direct causal role in the development of CHD.
        </p>
        <p class="headingAnchor" id="H4482486">
         <span class="h3">
          C-reactive protein
         </span>
         <span class="headingEndMark">
          —
         </span>
         A person's baseline level of inflammation, as assessed by the plasma concentration of CRP, predicts the long-term risk of a first MI, ischemic stroke, or peripheral artery disease  (
         <a class="graphic graphic_figure graphicRef69135" href="/z/d/graphic/69135.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid169">
          169-171
         </a>
         ]. The relationship between CRP and CVD is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1484.html" rel="external">
          "C-reactive protein in cardiovascular disease"
         </a>
         .)
        </p>
        <p>
         Measurement of CRP levels improves risk stratification [
         <a href="#rid172">
          172,173
         </a>
         ]. Several professional societies have issued statements or guidelines suggesting a role for the measurement of high-sensitivity CRP in patients at intermediate risk for CHD, in whom measurement may help direct further evaluation and therapy for primary prevention [
         <a href="#rid174">
          174-176
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1484.html" rel="external">
          "C-reactive protein in cardiovascular disease", section on 'Recommendations of others'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H835935">
         <span class="h3">
          Interleukin-6
         </span>
         <span class="headingEndMark">
          —
         </span>
         While the association between inflammation and the development of atherosclerotic disease is well-known, proving causation for any particular biomarker of inflammation has been difficult. IL-6 signals a downstream proinflammatory response by activating membrane-bound IL-6 receptors (IL-6R) on the cell surface. IL-6 and IL-6R appear to have a direct causal role in the development of CHD and may be a future target for therapeutic interventions to prevent CHD. (See
         <a class="medical medical_review" href="/z/d/html/13603.html" rel="external">
          "Pathogenesis of atherosclerosis", section on 'Inflammation'
         </a>
         .)
        </p>
        <p>
         The presence of Asp358Ala (rs2228145, formerly rs8192284), a variant allele of the
         <em>
          IL6R
         </em>
         gene encoding IL-6R, is associated with reduced membrane-bound IL-6R, resulting in decreased IL-6R signalling and less inflammation [
         <a href="#rid177">
          177
         </a>
         ]. Two large meta-analyses have confirmed the crucial role played by IL-6 and IL-6R in the generation of inflammation and the associated risk of CHD [
         <a href="#rid178">
          178,179
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a collaborative meta-analysis incorporating genetic and biomarker data from over 200,000 persons, each inherited copy of the Asp358Ala allele was independently associated with significantly increased soluble IL-6R levels, significantly decreased CRP levels, and significantly decreased risk of CHD (3.4 percent, 95% CI 1.8-5.0) [
         <a href="#rid178">
          178
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a Mendelian randomization analysis of over 133,000 persons analyzed for the single nucleotide polymorphism (SNP) rs7529229, which has strong linkage disequilibrium with Asp358Ala, each allele that contained the SNP rs7529229 was independently associated with significantly increased soluble IL-6R levels, significantly decreased CRP levels, and significantly decreased risk of CHD (5 percent decrease, 95% CI 3-7) [
         <a href="#rid179">
          179
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Both studies demonstrate an association between IL-6 and IL-6R levels and CHD that is dose-dependent (two variant alleles provided more benefit than one variant allele which provided more benefit than no variant alleles). Increased soluble (ie, circulating) IL-6R levels led to reduced membrane-bound IL-6R, thereby reducing signaling and downstream inflammation (reduced CRP levels). Taken together, these results provide evidence supporting a direct causal role of IL-6 and IL-6R in the development of CHD and suggest a future target for therapeutic interventions to prevent CHD.
        </p>
        <p class="headingAnchor" id="H4240764">
         <span class="h3">
          Myeloperoxidase
         </span>
         <span class="headingEndMark">
          —
         </span>
         Higher levels of the leukocyte enzyme myeloperoxidase, which is secreted during acute inflammation and promotes oxidation of lipoproteins, are associated with the presence of coronary disease and may be predictive of the presence of acute coronary syndrome in patients with chest pain [
         <a href="#rid180">
          180-183
         </a>
         ]. As an example, in a nested case-cohort study from the MONICA/KORA Augsburg involving 333 cases with CHD and 1727 controls followed for an average of nearly 11 years, patients with elevated myeloperoxidase levels had significantly greater likelihood of developing CHD after adjusting for traditional major cardiovascular risk factors (HR 1.70 for top tertile versus bottom two tertiles, 95% CI 1.25-2.30) [
         <a href="#rid183">
          183
         </a>
         ].
        </p>
        <p>
         Among patients with chronic systolic heart failure, elevated plasma myeloperoxidase levels have been associated with an increased likelihood of more advanced heart failure and may be predictive of a higher rate of adverse clinical outcomes [
         <a href="#rid184">
          184
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3506.html" rel="external">
          "Pathophysiology of heart failure with reduced ejection fraction: Hemodynamic alterations and remodeling", section on 'Other factors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4482589">
         <span class="h3">
          Other inflammatory markers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cardiovascular risk has also been associated with a variety of other markers of inflammation, though to a lesser extent than CRP. Elevated levels of white blood cells, erythrocyte sedimentation rates, IL-18, tumor necrosis factor alpha, transforming growth factor beta, soluble intercellular adhesion molecule-1, P-selectin, cathepsin S, and lipoprotein-associated phospholipase A2 have been reported as markers of increased CHD risk [
         <a href="#rid180">
          180-182,184-206
         </a>
         ]. While this adds further support to the role of inflammation in the development of atherosclerosis and CVD, most of these are not routinely used in clinical practice.
        </p>
        <p class="headingAnchor" id="H9708405">
         <span class="h2">
          HIV infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Widespread use of effective antiretroviral therapies (ARTs) in the treatment of human immunodeficiency virus (HIV) infection has led to increased longevity, exposing HIV-positive patients to many common medical conditions seen in an aging population, such as CVD. The risk of CVD in HIV-positive patients is predominantly influenced by the presence of traditional CVD risk factors. However, studies correcting for traditional CVD risk factors have shown higher rates of CHD and MI in HIV-positive patients compared with HIV-negative controls. (See
         <a class="medical medical_review" href="/z/d/html/3734.html" rel="external">
          "Epidemiology of cardiovascular disease and risk factors in patients with HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3739.html" rel="external">
          "Management of cardiovascular risk (including dyslipidemia) in patients with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H29702838">
         <span class="h2">
          Mediastinal radiation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Exposure to mediastinal or chest wall radiation during treatment for malignancy (eg, Hodgkin lymphoma, breast cancer) has been linked to subsequent development of cardiac disease, including pericardial disease, valvular disease, cardiomyopathy, and CHD. CHD following radiation tends to involve the ostia of the left main and right coronary arteries and may manifest as either angina or acute MI, potentially requiring revascularization. Furthermore, the risk of cardiac disease may be further increased by treatment with systemic anticancer agents (eg, anthracyclines,
         <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">
          trastuzumab
         </a>
         ).
        </p>
        <p>
         Females have a greater likelihood of having cardiovascular disease following radiation than males. In a network meta-analysis of 10 studies among 13,975 patients who received radiation for Hodgkin lymphoma, incident CVD events/mortality were more common in females (OR 3.74, 95% CI 2.44-5.72) as was all-cause mortality (OR 1.94, 95% CI 1.10-3.44) [
         <a href="#rid207">
          207
         </a>
         ]. This study was somewhat limited by high heterogeneity among studies analyzed.
        </p>
        <p>
         More information on the cardiac toxicity of mediastinal radiation and systemic anticancer therapy is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/90854.html" rel="external">
          "Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/107443.html" rel="external">
          "Risk and prevention of anthracycline cardiotoxicity"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2812.html" rel="external">
          "Cardiotoxicity of cancer chemotherapy agents other than anthracyclines, HER2-targeted agents, and fluoropyrimidines"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/774.html" rel="external">
          "Cardiotoxicity of trastuzumab and other HER2-targeted agents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/111731.html" rel="external">
          "Cardiotoxicity of radiation therapy for Hodgkin lymphoma and pediatric malignancies", section on 'Incidence of cardiovascular disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4485836">
         <span class="h2">
          Metabolic syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with the constellation of abdominal obesity, hypertension, diabetes, and dyslipidemia are considered to have the metabolic syndrome (also called the insulin resistance syndrome or syndrome X). Individuals with the metabolic syndrome have a markedly increased risk of coronary artery disease. This disorder is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1784.html" rel="external">
          "Metabolic syndrome (insulin resistance syndrome or syndrome X)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4482421">
         <span class="h2">
          Microalbuminuria
         </span>
         <span class="headingEndMark">
          —
         </span>
         Microalbuminuria (30 to 300 mg albumin/g creatinine in a urine specimen) is an indicator of greater risk for CVD and deterioration in renal function. Its presence appears to be a marker of early arterial disease. While microalbuminuria is accepted as an important risk factor for CVD and early cardiovascular mortality, the mechanism by which microalbuminuria is associated with CVD remains unclear. (See
         <a class="medical medical_review" href="/z/d/html/1545.html" rel="external">
          "Moderately increased albuminuria (microalbuminuria) and cardiovascular disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1336885969">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119659.html" rel="external">
          "Society guideline links: Assessment of cardiovascular risk"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2628519">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Importance
         </strong>
         – Cardiovascular disease (CVD) is the leading cause of death in most developed countries, with a prevalence that is rapidly increasing in resource-limited countries as well. Many risk factors for CVD are modifiable by specific preventive measures, therein offering an opportunity to reduce the burden of CVD worldwide. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          High-risk patients
         </strong>
         – Some patients without known coronary heart disease (CHD) have a risk of subsequent cardiovascular events that is equivalent to that of patients with established coronary disease. Examples of such high-risk patients include patients with noncoronary atherosclerotic arterial disease, diabetes mellitus, and chronic kidney disease (CKD). All patients with a CHD risk equivalent should be managed as aggressively as those with prior CHD. (See
         <a class="local">
          'Noncoronary atherosclerotic disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Family history
         </strong>
         – Family history is a significant independent risk factor for CHD, particularly among younger individuals with a family history of premature disease. (See
         <a class="local">
          'Family history'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypertension and dyslipidemia
         </strong>
         – Hypertension and dyslipidemia are well established risk factors for CVD. Effectively treating both hypertension and dyslipidemia can significantly reduce the risk of future CVD events. (See
         <a class="local">
          'Hypertension'
         </a>
         above and
         <a class="local">
          'Lipids and lipoproteins'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lifestyle factors
         </strong>
         – A variety of lifestyle factors, including cigarette smoking, diet, exercise, alcohol intake, and obesity, significantly impact the risk of developing CVD. (See
         <a class="local">
          'Lifestyle factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inflammation
         </strong>
         – Numerous markers of inflammation markers have been reported to be associated with increased risk of CVD. (See
         <a class="local">
          'Inflammation'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Laslett LJ, Alagona P Jr, Clark BA 3rd, et al. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J Am Coll Cardiol 2012; 60:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roth GA, Huffman MD, Moran AE, et al. Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation 2015; 132:1667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation 2019; 139:e56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet 2014; 383:1899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367:1747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet 1999; 353:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med 2012; 366:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Webber BJ, Seguin PG, Burnett DG, et al. Prevalence of and risk factors for autopsy-determined atherosclerosis among US service members, 2001-2011. JAMA 2012; 308:2577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooper R, Cutler J, Desvigne-Nickens P, et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. Circulation 2000; 102:3137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smolina K, Wright FL, Rayner M, Goldacre MJ. Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study. BMJ 2012; 344:d8059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt M, Jacobsen JB, Lash TL, et al. 25 year trends in first time hospitalisation for acute myocardial infarction, subsequent short and long term mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort study. BMJ 2012; 344:e356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bandosz P, O'Flaherty M, Drygas W, et al. Decline in mortality from coronary heart disease in Poland after socioeconomic transformation: modelling study. BMJ 2012; 344:d8136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koton S, Schneider AL, Rosamond WD, et al. Stroke incidence and mortality trends in US communities, 1987 to 2011. JAMA 2014; 312:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George J, Rapsomaniki E, Pujades-Rodriguez M, et al. How Does Cardiovascular Disease First Present in Women and Men? Incidence of 12 Cardiovascular Diseases in a Contemporary Cohort of 1,937,360 People. Circulation 2015; 132:1320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J 2014; 35:2950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ritchey MD, Wall HK, Gillespie C, et al. Million hearts: prevalence of leading cardiovascular disease risk factors--United States, 2005-2012. MMWR Morb Mortal Wkly Rep 2014; 63:462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation 2014; 129:e28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hajat C, Harrison O. The Abu Dhabi Cardiovascular Program: the continuation of Framingham. Prog Cardiovasc Dis 2010; 53:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reddy KS, Satija A. The Framingham Heart Study: impact on the prevention and control of cardiovascular diseases in India. Prog Cardiovasc Dis 2010; 53:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vartiainen E, Laatikainen T, Peltonen M, et al. Thirty-five-year trends in cardiovascular risk factors in Finland. Int J Epidemiol 2010; 39:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran AE, Forouzanfar MH, Roth GA, et al. The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study. Circulation 2014; 129:1493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran AE, Forouzanfar MH, Roth GA, et al. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the Global Burden of Disease 2010 study. Circulation 2014; 129:1483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yusuf S, Rangarajan S, Teo K, et al. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med 2014; 371:818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007; 297:1197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vasan RS, Sullivan LM, Wilson PW, et al. Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Intern Med 2005; 142:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stamler J, Stamler R, Neaton JD, et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA 1999; 282:2012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Global Cardiovascular Risk Consortium, Magnussen C, Ojeda FM, et al. Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality. N Engl J Med 2023; 389:1273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yusuf S, Joseph P, Rangarajan S, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet 2020; 395:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel SA, Winkel M, Ali MK, et al. Cardiovascular mortality associated with 5 leading risk factors: national and state preventable fractions estimated from survey data. Ann Intern Med 2015; 163:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson R, Lawes CM, Bennett DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005; 365:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lowe LP, Greenland P, Ruth KJ, et al. Impact of major cardiovascular disease risk factors, particularly in combination, on 22-year mortality in women and men. Arch Intern Med 1998; 158:2007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asia Pacific Cohort Studies Collaboration. Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacific region. Circulation 2005; 112:3384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson PW. Established risk factors and coronary artery disease: the Framingham Study. Am J Hypertens 1994; 7:7S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridker PM. Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med 1999; 130:933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation 1999; 99:1165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hennekens CH. Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation 1998; 97:1095.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Canto JG, Iskandrian AE. Major risk factors for cardiovascular disease: debunking the "only 50%" myth. JAMA 2003; 290:947.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenland P, Knoll MD, Stamler J, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003; 290:891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290:898.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Canto JG, Kiefe CI, Rogers WJ, et al. Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction. JAMA 2011; 306:2120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens SL, Wood S, Koshiaris C, et al. Blood pressure variability and cardiovascular disease: systematic review and meta-analysis. BMJ 2016; 354:i4098.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gosmanova EO, Mikkelsen MK, Molnar MZ, et al. Association of Systolic Blood Pressure Variability With Mortality, Coronary Heart Disease, Stroke, and Renal Disease. J Am Coll Cardiol 2016; 68:1375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bangalore S, Breazna A, DeMicco DA, et al. Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial. J Am Coll Cardiol 2015; 65:1539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim MK, Han K, Kim HS, et al. Cholesterol variability and the risk of mortality, myocardial infarction, and stroke: a nationwide population-based study. Eur Heart J 2017; 38:3560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bangalore S, Fayyad R, Laskey R, et al. Body-Weight Fluctuations and Outcomes in Coronary Disease. N Engl J Med 2017; 376:1332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gregg EW, Cheng YJ, Cadwell BL, et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA 2005; 293:1868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation 2010; 121:586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang Q, Cogswell ME, Flanders WD, et al. Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adults. JAMA 2012; 307:1273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ford ES, Greenlund KJ, Hong Y. Ideal cardiovascular health and mortality from all causes and diseases of the circulatory system among adults in the United States. Circulation 2012; 125:987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hwang SJ, Onuma O, Massaro JM, et al. Maintenance of Ideal Cardiovascular Health and Coronary Artery Calcium Progression in Low-Risk Men and Women in the Framingham Heart Study. Circ Cardiovasc Imaging 2018; 11:e006209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dong C, Rundek T, Wright CB, et al. Ideal cardiovascular health predicts lower risks of myocardial infarction, stroke, and vascular death across whites, blacks, and hispanics: the northern Manhattan study. Circulation 2012; 125:2975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akesson A, Larsson SC, Discacciati A, Wolk A. Low-risk diet and lifestyle habits in the primary prevention of myocardial infarction in men: a population-based prospective cohort study. J Am Coll Cardiol 2014; 64:1299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Record NB, Onion DK, Prior RE, et al. Community-wide cardiovascular disease prevention programs and health outcomes in a rural county, 1970-2010. JAMA 2015; 313:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chomistek AK, Chiuve SE, Eliassen AH, et al. Healthy lifestyle in the primordial prevention of cardiovascular disease among young women. J Am Coll Cardiol 2015; 65:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li Y, Pan A, Wang DD, et al. Impact of Healthy Lifestyle Factors on Life Expectancies in the US Population. Circulation 2018; 138:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramírez-Vélez R, Saavedra JM, Lobelo F, et al. Ideal Cardiovascular Health and Incident Cardiovascular Disease Among Adults: A Systematic Review and Meta-analysis. Mayo Clin Proc 2018; 93:1589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang ZJ, Liu J, Ge JP, et al. Prevalence of cardiovascular disease risk factor in the Chinese population: the 2007-2008 China National Diabetes and Metabolic Disorders Study. Eur Heart J 2012; 33:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li S, Chen W, Srinivasan SR, et al. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA 2003; 290:2271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raitakari OT, Juonala M, Kähönen M, et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA 2003; 290:2277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis PH, Dawson JD, Riley WA, Lauer RM. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: The Muscatine Study. Circulation 2001; 104:2815.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox CS, Coady S, Sorlie PD, et al. Trends in cardiovascular complications of diabetes. JAMA 2004; 292:2495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox CS, Pencina MJ, Wilson PW, et al. Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study. Diabetes Care 2008; 31:1582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Njølstad I, Arnesen E, Lund-Larsen PG. Smoking, serum lipids, blood pressure, and sex differences in myocardial infarction. A 12-year follow-up of the Finnmark Study. Circulation 1996; 93:450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prescott E, Hippe M, Schnohr P, et al. Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ 1998; 316:1043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103:1245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris T, Cook EF, Kannel WB, Goldman L. Proportional hazards analysis of risk factors for coronary heart disease in individuals aged 65 or older. The Framingham Heart Study. J Am Geriatr Soc 1988; 36:1023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson PW, Kannel WB. Hypercholesterolemia and Coronary Risk in the Elderly: The Framingham Study. Am J Geriatr Cardiol 1993; 2:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hung J, Whitford EG, Parsons RW, Hillman DR. Association of sleep apnoea with myocardial infarction in men. Lancet 1990; 336:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dannenberg AL, Keller JB, Wilson PW, Castelli WP. Leisure time physical activity in the Framingham Offspring Study. Description, seasonal variation, and risk factor correlates. Am J Epidemiol 1989; 129:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Powell KE, Thompson PD, Caspersen CJ, Kendrick JS. Physical activity and the incidence of coronary heart disease. Annu Rev Public Health 1987; 8:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savji N, Rockman CB, Skolnick AH, et al. Association between advanced age and vascular disease in different arterial territories: a population database of over 3.6 million subjects. J Am Coll Cardiol 2013; 61:1736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tunstall-Pedoe H, Kuulasmaa K, Mähönen M, et al. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999; 353:1547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kappert K, Böhm M, Schmieder R, et al. Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET). Circulation 2012; 126:934.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease. The Framingham Study. Ann Intern Med 1978; 89:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charchar FJ, Bloomer LD, Barnes TA, et al. Inheritance of coronary artery disease in men: an analysis of the role of the Y chromosome. Lancet 2012; 379:915.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sesso HD, Lee IM, Gaziano JM, et al. Maternal and paternal history of myocardial infarction and risk of cardiovascular disease in men and women. Circulation 2001; 104:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andresdottir MB, Sigurdsson G, Sigvaldason H, et al. Fifteen percent of myocardial infarctions and coronary revascularizations explained by family history unrelated to conventional risk factors. The Reykjavik Cohort Study. Eur Heart J 2002; 23:1655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roncaglioni MC, Santoro L, D'Avanzo B, et al. Role of family history in patients with myocardial infarction. An Italian case-control study. GISSI-EFRIM Investigators. Circulation 1992; 85:2065.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lloyd-Jones DM, Nam BH, D'Agostino RB Sr, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA 2004; 291:2204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murabito JM, Pencina MJ, Nam BH, et al. Sibling cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults. JAMA 2005; 294:3117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sivapalaratnam S, Boekholdt SM, Trip MD, et al. Family history of premature coronary heart disease and risk prediction in the EPIC-Norfolk prospective population study. Heart 2010; 96:1985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Otaki Y, Gransar H, Berman DS, et al. Impact of family history of coronary artery disease in young individuals (from the CONFIRM registry). Am J Cardiol 2013; 111:1081.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berg AO, Baird MA, Botkin JR, et al. National Institutes of Health State-of-the-Science Conference Statement: Family History and Improving Health. Ann Intern Med 2009; 151:872.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:2889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel J, Al Rifai M, Scheuner MT, et al. Basic vs More Complex Definitions of Family History in the Prediction of Coronary Heart Disease: The Multi-Ethnic Study of Atherosclerosis. Mayo Clin Proc 2018; 93:1213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation 2017; 135:e146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bachmann JM, Willis BL, Ayers CR, et al. Association between family history and coronary heart disease death across long-term follow-up in men: the Cooper Center Longitudinal Study. Circulation 2012; 125:3092.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chow CK, Islam S, Bautista L, et al. Parental history and myocardial infarction risk across the world: the INTERHEART Study. J Am Coll Cardiol 2011; 57:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nielsen M, Andersson C, Gerds TA, et al. Familial clustering of myocardial infarction in first-degree relatives: a nationwide study. Eur Heart J 2013; 34:1198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paixao AR, Berry JD, Neeland IJ, et al. Coronary artery calcification and family history of myocardial infarction in the Dallas heart study. JACC Cardiovasc Imaging 2014; 7:679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ranthe MF, Carstensen L, Oyen N, et al. Family history of premature death and risk of early onset cardiovascular disease. J Am Coll Cardiol 2012; 60:814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zöller B, Li X, Sundquist J, Sundquist K. Multiplex sibling history of coronary heart disease is a strong risk factor for coronary heart disease. Eur Heart J 2012; 33:2849.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kral BG, Becker LC, Vaidya D, et al. Noncalcified coronary plaque volumes in healthy people with a family history of early onset coronary artery disease. Circ Cardiovasc Imaging 2014; 7:446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qureshi N, Armstrong S, Dhiman P, et al. Effect of adding systematic family history enquiry to cardiovascular disease risk assessment in primary care: a matched-pair, cluster randomized trial. Ann Intern Med 2012; 156:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murabito JM, Nam BH, D'Agostino RB Sr, et al. Accuracy of offspring reports of parental cardiovascular disease history: the Framingham Offspring Study. Ann Intern Med 2004; 140:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miura K, Daviglus ML, Dyer AR, et al. Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: the Chicago Heart Association Detection Project in Industry. Arch Intern Med 2001; 161:1501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muntner P, Whittle J, Lynch AI, et al. Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study. Ann Intern Med 2015; 163:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Genest JJ Jr, Martin-Munley SS, McNamara JR, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992; 85:2025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ference BA, Bhatt DL, Catapano AL, et al. Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA 2019; 322:1381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernández-Friera L, Fuster V, López-Melgar B, et al. Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk Factors. J Am Coll Cardiol 2017; 70:2979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mora S, Otvos JD, Rifai N, et al. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009; 119:931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979; 59:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979; 2:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med 2004; 164:1422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37:1595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zavaroni I, Bonora E, Pagliara M, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 1989; 320:702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singer DE, Nathan DM, Anderson KM, et al. Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 1992; 41:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerstein HC, Pais P, Pogue J, Yusuf S. Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study. J Am Coll Cardiol 1999; 33:612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Delaimy WK, Merchant AT, Rimm EB, et al. Effect of type 2 diabetes and its duration on the risk of peripheral arterial disease among men. Am J Med 2004; 116:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaccaro O, Eberly LE, Neaton JD, et al. Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial. Arch Intern Med 2004; 164:1438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Sleight P, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292:2217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013; 382:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1.
          </a>
         </li>
         <li class="breakAll">
          Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hakeem A, Bhatti S, Dillie KS, et al. Predictive value of myocardial perfusion single-photon emission computed tomography and the impact of renal function on cardiac death. Circulation 2008; 118:2540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilhelmsson C, Vedin JA, Elmfeldt D, et al. Smoking and myocardial infarction. Lancet 1975; 1:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang Y, Chen Z, Chen B, et al. Dietary sugar consumption and health: umbrella review. BMJ 2023; 381:e071609.
          </a>
         </li>
         <li class="breakAll">
          https://health.gov/dietaryguidelines/2015/guidelines/chapter-1/a-closer-look-inside-healthy-eating-patterns/ (Accessed on March 19, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paffenbarger RS Jr, Hyde RT, Wing AL, et al. The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. N Engl J Med 1993; 328:538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leon AS, Connett J, Jacobs DR Jr, Rauramaa R. Leisure-time physical activity levels and risk of coronary heart disease and death. The Multiple Risk Factor Intervention Trial. JAMA 1987; 258:2388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee DC, Sui X, Artero EG, et al. Long-term effects of changes in cardiorespiratory fitness and body mass index on all-cause and cardiovascular disease mortality in men: the Aerobics Center Longitudinal Study. Circulation 2011; 124:2483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kubota Y, Evenson KR, Maclehose RF, et al. Physical Activity and Lifetime Risk of Cardiovascular Disease and Cancer. Med Sci Sports Exerc 2017; 49:1599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandvik L, Erikssen J, Thaulow E, et al. Physical fitness as a predictor of mortality among healthy, middle-aged Norwegian men. N Engl J Med 1993; 328:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blair SN, Kohl HW 3rd, Paffenbarger RS Jr, et al. Physical fitness and all-cause mortality. A prospective study of healthy men and women. JAMA 1989; 262:2395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LaMonte MJ, Eisenman PA, Adams TD, et al. Cardiorespiratory fitness and coronary heart disease risk factors: the LDS Hospital Fitness Institute cohort. Circulation 2000; 102:1623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laukkanen JA, Lakka TA, Rauramaa R, et al. Cardiovascular fitness as a predictor of mortality in men. Arch Intern Med 2001; 161:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myers J, Prakash M, Froelicher V, et al. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 2002; 346:793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barlow CE, Defina LF, Radford NB, et al. Cardiorespiratory fitness and long-term survival in "low-risk" adults. J Am Heart Assoc 2012; 1:e001354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mandsager K, Harb S, Cremer P, et al. Association of Cardiorespiratory Fitness With Long-term Mortality Among Adults Undergoing Exercise Treadmill Testing. JAMA Netw Open 2018; 1:e183605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Held C, Iqbal R, Lear SA, et al. Physical activity levels, ownership of goods promoting sedentary behaviour and risk of myocardial infarction: results of the INTERHEART study. Eur Heart J 2012; 33:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berry JD, Willis B, Gupta S, et al. Lifetime risks for cardiovascular disease mortality by cardiorespiratory fitness levels measured at ages 45, 55, and 65 years in men. The Cooper Center Longitudinal Study. J Am Coll Cardiol 2011; 57:1604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clausen JSR, Marott JL, Holtermann A, et al. Midlife Cardiorespiratory Fitness and the Long-Term Risk of Mortality: 46 Years of Follow-Up. J Am Coll Cardiol 2018; 72:987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Imboden MT, Harber MP, Whaley MH, et al. Cardiorespiratory Fitness and Mortality in Healthy Men and Women. J Am Coll Cardiol 2018; 72:2283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho SS, Dhaliwal SS, Hills AP, Pal S. The effect of 12 weeks of aerobic, resistance or combination exercise training on cardiovascular risk factors in the overweight and obese in a randomized trial. BMC Public Health 2012; 12:704.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kerksick C, Thomas A, Campbell B, et al. Effects of a popular exercise and weight loss program on weight loss, body composition, energy expenditure and health in obese women. Nutr Metab (Lond) 2009; 6:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mekary RA, Grøntved A, Despres JP, et al. Weight training, aerobic physical activities, and long-term waist circumference change in men. Obesity (Silver Spring) 2015; 23:461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hunter GR, Bryan DR, Wetzstein CJ, et al. Resistance training and intra-abdominal adipose tissue in older men and women. Med Sci Sports Exerc 2002; 34:1023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross R. Effects of diet- and exercise-induced weight loss on visceral adipose tissue in men and women. Sports Med 1997; 24:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curioni CC, Lourenço PM. Long-term weight loss after diet and exercise: a systematic review. Int J Obes (Lond) 2005; 29:1168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mann S, Beedie C, Jimenez A. Differential effects of aerobic exercise, resistance training and combined exercise modalities on cholesterol and the lipid profile: review, synthesis and recommendations. Sports Med 2014; 44:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piercy KL, Trolano RP, Ballard RM, et al.. The Physical Activity Guidelines for Americans. J Am Med Assoc 2018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 2014; 311:806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eckel RH, York DA, Rössner S, et al. Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: executive summary. Circulation 2004; 110:2968.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999; 341:1097.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolk R, Berger P, Lennon RJ, et al. Association between plasma adiponectin levels and unstable coronary syndromes. Eur Heart J 2007; 28:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tirosh A, Shai I, Afek A, et al. Adolescent BMI trajectory and risk of diabetes versus coronary disease. N Engl J Med 2011; 364:1315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson PW, Bozeman SR, Burton TM, et al. Prediction of first events of coronary heart disease and stroke with consideration of adiposity. Circulation 2008; 118:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 2014; 129:S102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Twig G, Yaniv G, Levine H, et al. Body-Mass Index in 2.3 Million Adolescents and Cardiovascular Death in Adulthood. N Engl J Med 2016; 374:2430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walli-Attaei M, Rosengren A, Rangarajan S, et al. Metabolic, behavioural, and psychosocial risk factors and cardiovascular disease in women compared with men in 21 high-income, middle-income, and low-income countries: an analysis of the PURE study. Lancet 2022; 400:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010; 375:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antonopoulos AS, Angelopoulos A, Papanikolaou P, et al. Biomarkers of Vascular Inflammation for Cardiovascular Risk Prognostication: A Meta-Analysis. JACC Cardiovasc Imaging 2022; 15:460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97:2007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koenig W, Sund M, Fröhlich M, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007; 297:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson PW, Pencina M, Jacques P, et al. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes 2008; 1:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009; 25:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           US Preventive Services Task Force, Curry SJ, Krist AH, et al. Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors: US Preventive Services Task Force Recommendation Statement. JAMA 2018; 320:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reich D, Patterson N, Ramesh V, et al. Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels. Am J Hum Genet 2007; 80:716.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           IL6R Genetics Consortium Emerging Risk Factors Collaboration, Sarwar N, Butterworth AS, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012; 379:1205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Swerdlow DI, Holmes MV, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 2012; 379:1214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003; 349:1595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zheng L, Nukuna B, Brennan ML, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004; 114:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001; 286:2136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karakas M, Koenig W, Zierer A, et al. Myeloperoxidase is associated with incident coronary heart disease independently of traditional risk factors: results from the MONICA/KORA Augsburg study. J Intern Med 2012; 271:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang WH, Tong W, Troughton RW, et al. Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol 2007; 49:2364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horne BD, Anderson JL, John JM, et al. Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol 2005; 45:1638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350:1387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351:2599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woods A, Brull DJ, Humphries SE, Montgomery HE. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J 2000; 21:1574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101:1767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blankenberg S, Tiret L, Bickel C, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002; 106:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tiret L, Godefroy T, Lubos E, et al. Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation 2005; 112:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valgimigli M, Ceconi C, Malagutti P, et al. Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study. Circulation 2005; 111:863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haim M, Tanne D, Boyko V, et al. Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease. Data from the Bezafibrate Infarction Prevention (BIP) Study. J Am Coll Cardiol 2002; 39:1133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blankenberg S, Rupprecht HJ, Bickel C, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001; 104:1336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malik I, Danesh J, Whincup P, et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 2001; 358:971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roldán V, Marín F, Lip GY, Blann AD. Soluble E-selectin in cardiovascular disease and its risk factors. A review of the literature. Thromb Haemost 2003; 90:1007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oei HH, van der Meer IM, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005; 111:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004; 109:837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Packard CJ, O'Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000; 343:1148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koenig W, Khuseyinova N, Löwel H, et al. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 2004; 110:1903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blake GJ, Dada N, Fox JC, et al. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 2001; 38:1302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garza CA, Montori VM, McConnell JP, et al. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc 2007; 82:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jobs E, Ingelsson E, Risérus U, et al. Association between serum cathepsin S and mortality in older adults. JAMA 2011; 306:1113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agarwal I, Glazer NL, Barasch E, et al. Fibrosis-related biomarkers and risk of total and cause-specific mortality: the cardiovascular health study. Am J Epidemiol 2014; 179:1331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khalid Y, Fradley M, Dasu N, et al. Gender disparity in cardiovascular mortality following radiation therapy for Hodgkin's lymphoma: a systematic review. Cardiooncology 2020; 6:12.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1506 Version 76.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23257320" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25530442" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26503749" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Global and regional patterns in cardiovascular mortality from 1990 to 2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30700139" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24881994" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16731270" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10023892" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Lifetime risk of developing coronary heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22276822" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Lifetime risks of cardiovascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23268516" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Prevalence of and risk factors for autopsy-determined atherosclerosis among US service members, 2001-2011.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11120707" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22279113" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22279115" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : 25 year trends in first time hospitalisation for acute myocardial infarction, subsequent short and long term mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22279114" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Decline in mortality from coronary heart disease in Poland after socioeconomic transformation: modelling study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25027141" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Stroke incidence and mortality trends in US communities, 1987 to 2011.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26330414" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : How Does Cardiovascular Disease First Present in Women and Men? Incidence of 12 Cardiovascular Diseases in a Contemporary Cohort of 1,937,360 People.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25139896" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Cardiovascular disease in Europe 2014: epidemiological update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24871251" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Million hearts: prevalence of leading cardiovascular disease risk factors--United States, 2005-2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24352519" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Heart disease and stroke statistics--2014 update: a report from the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20620423" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The Abu Dhabi Cardiovascular Program: the continuation of Framingham.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20620422" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The Framingham Heart Study: impact on the prevention and control of cardiovascular diseases in India.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19959603" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Thirty-five-year trends in cardiovascular risk factors in Finland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24573351" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24573352" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the Global Burden of Disease 2010 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25162888" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Cardiovascular risk and events in 17 low-, middle-, and high-income countries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17374814" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : One-year cardiovascular event rates in outpatients with atherothrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15364185" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15767617" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Relative importance of borderline and elevated levels of coronary heart disease risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10591383" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37632466" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31492503" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26121190" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Cardiovascular mortality associated with 5 leading risk factors: national and state preventable fractions estimated from survey data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15680460" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9778200" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Impact of major cardiovascular disease risk factors, particularly in combination, on 22-year mortality in women and men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16301345" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacific region.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7946184" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Established risk factors and coronary artery disease: the Framingham Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9603539" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Prediction of coronary heart disease using risk factor categories.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10375342" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Evaluating novel cardiovascular risk factors: can we better predict heart attacks?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10069784" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12485966" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9742976" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24352797" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9531257" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12928473" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Major risk factors for cardiovascular disease: debunking the "only 50%" myth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12928465" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Major risk factors as antecedents of fatal and nonfatal coronary heart disease events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12928466" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Prevalence of conventional risk factors in patients with coronary heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22089719" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27511067" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Blood pressure variability and cardiovascular disease: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27659458" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Association of Systolic Blood Pressure Variability With Mortality, Coronary Heart Disease, Stroke, and Renal Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25881936" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29069458" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Cholesterol variability and the risk of mortality, myocardial infarction, and stroke: a nationwide population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28379800" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Body-Weight Fluctuations and Outcomes in Coronary Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15840861" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Secular trends in cardiovascular disease risk factors according to body mass index in US adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20089546" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22427615" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22291126" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Ideal cardiovascular health and mortality from all causes and diseases of the circulatory system among adults in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29305347" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Maintenance of Ideal Cardiovascular Health and Coronary Artery Calcium Progression in Low-Risk Men and Women in the Framingham Heart Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22619283" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Ideal cardiovascular health predicts lower risks of myocardial infarction, stroke, and vascular death across whites, blacks, and hispanics: the northern Manhattan study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25257629" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Low-risk diet and lifestyle habits in the primary prevention of myocardial infarction in men: a population-based prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25585326" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Community-wide cardiovascular disease prevention programs and health outcomes in a rural county, 1970-2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25572509" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Healthy lifestyle in the primordial prevention of cardiovascular disease among young women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29712712" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Impact of Healthy Lifestyle Factors on Life Expectancies in the US Population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30274906" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Ideal Cardiovascular Health and Incident Cardiovascular Disease Among Adults: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21719451" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Prevalence of cardiovascular disease risk factor in the Chinese population: the 2007-2008 China National Diabetes and Metabolic Disorders Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14600185" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14600186" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11733400" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: The Muscatine Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15562129" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Trends in cardiovascular complications of diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18458146" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8565161" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Smoking, serum lipids, blood pressure, and sex differences in myocardial infarction. A 12-year follow-up of the Finnmark Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9552903" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Smoking and risk of myocardial infarction in women and men: longitudinal population study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11238268" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2971709" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Proportional hazards analysis of risk factors for coronary heart disease in individuals aged 65 or older. The Framingham Heart Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11416288" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Hypercholesterolemia and Coronary Risk in the Elderly: The Framingham Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1973968" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Association of sleep apnoea with myocardial infarction in men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2910074" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Leisure time physical activity in the Framingham Offspring Study. Description, seasonal variation, and risk factor correlates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3555525" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Physical activity and the incidence of coronary heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23500290" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Association between advanced age and vascular disease in different arterial territories: a population database of over 3.6 million subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10334252" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18212285" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : General cardiovascular risk profile for use in primary care: the Framingham Heart Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22829023" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/677576" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Menopause and coronary heart disease. The Framingham Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22325189" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Inheritance of coronary artery disease in men: an analysis of the role of the Y chromosome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11468199" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Maternal and paternal history of myocardial infarction and risk of cardiovascular disease in men and women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12398822" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Fifteen percent of myocardial infarctions and coronary revascularizations explained by family history unrelated to conventional risk factors. The Reykjavik Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1591825" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Role of family history in patients with myocardial infarction. An Italian case-control study. GISSI-EFRIM Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15138242" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16380592" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Sibling cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20962344" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Family history of premature coronary heart disease and risk prediction in the EPIC-Norfolk prospective population study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23411105" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Impact of family history of coronary artery disease in young individuals (from the CONFIRM registry).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19884615" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : National Institutes of Health State-of-the-Science Conference Statement: Family History and Improving Health.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24239923" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29555305" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Basic vs More Complex Definitions of Family History in the Prediction of Coronary Heart Disease: The Multi-Ethnic Study of Atherosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28122885" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22623718" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Association between family history and coronary heart disease death across long-term follow-up in men: the Cooper Center Longitudinal Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21272754" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Parental history and myocardial infarction risk across the world: the INTERHEART Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23297314" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Familial clustering of myocardial infarction in first-degree relatives: a nationwide study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24954461" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Coronary artery calcification and family history of myocardial infarction in the Dallas heart study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22917005" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Family history of premature death and risk of early onset cardiovascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22719024" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Multiplex sibling history of coronary heart disease is a strong risk factor for coronary heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24577355" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Noncalcified coronary plaque volumes in healthy people with a family history of early onset coronary artery disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22351711" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Effect of adding systematic family history enquiry to cardiovascular disease risk assessment in primary care: a matched-pair, cluster randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15023709" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Accuracy of offspring reports of parental cardiovascular disease history: the Framingham Offspring Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11427097" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: the Chicago Heart Association Detection Project in Industry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12493255" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26215765" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17563527" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12485966" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1534286" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Familial lipoprotein disorders in patients with premature coronary artery disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31475726" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7566020" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9613910" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8801446" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29241485" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk Factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19204302" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/758126" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Diabetes and cardiovascular risk factors: the Framingham study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/520114" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15249351" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3056758" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Banting lecture 1988. Role of insulin resistance in human disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2646537" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1733810" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10080459" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14969651" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Effect of type 2 diabetes and its duration on the risk of peripheral arterial disease among men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15249353" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10639539" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13678872" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15536108" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23727170" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11904577" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11904577" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19047585" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Predictive value of myocardial perfusion single-photon emission computed tomography and the impact of renal function on cardiac death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/48609" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Smoking and myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37019448" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Dietary sugar consumption and health: umbrella review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37019448" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Dietary sugar consumption and health: umbrella review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8426621" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : The association of changes in physical-activity level and other lifestyle characteristics with mortality among men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3669210" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Leisure-time physical activity levels and risk of coronary heart disease and death. The Multiple Risk Factor Intervention Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22144631" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Long-term effects of changes in cardiorespiratory fitness and body mass index on all-cause and cardiovascular disease mortality in men: the Aerobics Center Longitudinal Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28350711" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Physical Activity and Lifetime Risk of Cardiovascular Disease and Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8426620" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Physical fitness as a predictor of mortality among healthy, middle-aged Norwegian men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2795824" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Physical fitness and all-cause mortality. A prospective study of healthy men and women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11015338" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Cardiorespiratory fitness and coronary heart disease risk factors: the LDS Hospital Fitness Institute cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11268224" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Cardiovascular fitness as a predictor of mortality in men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11893790" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Exercise capacity and mortality among men referred for exercise testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23130161" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Cardiorespiratory fitness and long-term survival in "low-risk" adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30646252" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Association of Cardiorespiratory Fitness With Long-term Mortality Among Adults Undergoing Exercise Treadmill Testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22238330" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Physical activity levels, ownership of goods promoting sedentary behaviour and risk of myocardial infarction: results of the INTERHEART study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21474041" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Lifetime risks for cardiovascular disease mortality by cardiorespiratory fitness levels measured at ages 45, 55, and 65 years in men. The Cooper Center Longitudinal Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30139444" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Midlife Cardiorespiratory Fitness and the Long-Term Risk of Mortality: 46 Years of Follow-Up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30384883" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Cardiorespiratory Fitness and Mortality in Healthy Men and Women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23006411" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : The effect of 12 weeks of aerobic, resistance or combination exercise training on cardiovascular risk factors in the overweight and obese in a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19442301" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Effects of a popular exercise and weight loss program on weight loss, body composition, energy expenditure and health in obese women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25530447" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Weight training, aerobic physical activities, and long-term waist circumference change in men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12048332" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Resistance training and intra-abdominal adipose tissue in older men and women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11832527" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9257410" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Effects of diet- and exercise-induced weight loss on visceral adipose tissue in men and women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15925949" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Long-term weight loss after diet and exercise: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24174305" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Differential effects of aerobic exercise, resistance training and combined exercise modalities on cholesterol and the lipid profile: review, synthesis and recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : The Physical Activity Guidelines for Americans
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24570244" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Prevalence of childhood and adult obesity in the United States, 2011-2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15520336" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: executive summary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10511607" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : Body-mass index and mortality in a prospective cohort of U.S. adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17090613" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Association between plasma adiponectin levels and unstable coronary syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21470009" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : Adolescent BMI trajectory and risk of diabetes versus coronary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18591432" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : Prediction of first events of coronary heart disease and stroke with consideration of adiposity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24222017" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27074389" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : Body-Mass Index in 2.3 Million Adolescents and Cardiovascular Death in Adulthood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36088949" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : Metabolic, behavioural, and psychosocial risk factors and cardiovascular disease in women compared with men in 21 high-income, middle-income, and low-income countries: an analysis of the PURE study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20031199" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34801448" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : Biomarkers of Vascular Inflammation for Cardiovascular Risk Prognostication: A Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9610529" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9892589" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9727541" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17299196" id="rid171" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          172 : Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20031795" id="rid172" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          173 : C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12551878" id="rid173" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          174 : Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19812802" id="rid174" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          175 : 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29998297" id="rid175" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          176 : Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors: US Preventive Services Task Force Recommendation Statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17357077" id="rid176" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          177 : Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22421339" id="rid177" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          178 : Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22421340" id="rid178" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          179 : The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14573731" id="rid179" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          180 : Prognostic value of myeloperoxidase in patients with chest pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15314690" id="rid180" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          181 : Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11694155" id="rid181" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          182 : Association between myeloperoxidase levels and risk of coronary artery disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21535251" id="rid182" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          183 : Myeloperoxidase is associated with incident coronary heart disease independently of traditional risk factors: results from the MONICA/KORA Augsburg study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17572253" id="rid183" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          184 : Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15893180" id="rid184" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          185 : Which white blood cell subtypes predict increased cardiovascular risk?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15070788" id="rid185" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          186 : C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15602020" id="rid186" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          187 : Inflammatory markers and the risk of coronary heart disease in men and women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10988009" id="rid187" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          188 : Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10769275" id="rid188" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          189 : Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12093765" id="rid189" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          190 : Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16043644" id="rid190" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          191 : Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15699251" id="rid191" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          192 : Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10733371" id="rid192" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          193 : C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11157711" id="rid193" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          194 : Soluble P-selectin and the risk of future cardiovascular events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11923036" id="rid194" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          195 : Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease. Data from the Bezafibrate Infarction Prevention (BIP) Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11560847" id="rid195" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          196 : Circulating cell adhesion molecules and death in patients with coronary artery disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11583751" id="rid196" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          197 : Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14652631" id="rid197" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          198 : Soluble E-selectin in cardiovascular disease and its risk factors. A review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15699277" id="rid198" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          199 : Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14757686" id="rid199" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          200 : Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11036120" id="rid200" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          201 : Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15451783" id="rid201" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          202 : Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11691499" id="rid202" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          203 : A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17290721" id="rid203" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          204 : Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21878432" id="rid204" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          205 : Association between serum cathepsin S and mortality in older adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24771724" id="rid205" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          206 : Fibrosis-related biomarkers and risk of total and cause-specific mortality: the cardiovascular health study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32774890" id="rid206" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          207 : Gender disparity in cardiovascular mortality following radiation therapy for Hodgkin's lymphoma: a systematic review.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
